SAP News

Since the 2018 guideline’s publication, additional non-statin therapies such as bempedoic acid, evinacumab, and inclisiran, have been approved by the FDA for the management of hypercholesterolemia.

The extra surveillance by a specialty pharmacy teams allows for faster initiation of therapy, earlier recognition of adverse effects, and promotes patient safety.

Kimlin Tam Ashing, PhD, discusses her research assessing effective interventions in ethnic minority communities to increase colorectal cancer screenings.

Pharmacists, in particular, must be cautious and deliberate in using ChatGPT to ensure that its benefits are fully realized while minimizing risk and misinformation.

Asking pharmacists to do even more work while paring down their support is not a sustainable solution to increasing costs.

Studies show that patients who had pharmacists as part of their transplant-related care had a significant improvement in clinical outcomes.

Given the increasing value of patient satisfaction in determining the quality of care in the hospital reimbursement model, research is flourishing with a focus on identifying the factors that could positively influence patient satisfaction outcomes.

Study authors determined that prevention or mitigation of myelotoxic events that destroy bone marrow can potentially lessen myelosuppression in patients with ES-SCLC.

Register and Attend to Qualify for a OneStop Generics Rebate of Up to $6,000.

Data show that dose-response relationships and long-term safety of ICS in people with chronic obstructive pulmonary disease are unclear and require further investigation.

Transplant patients must adhere to lifelong regimens and those caring for them must consider their regimen as the patients intersect with different parts of the health care system.

Medication Safety Week is observed April 1–7. With the theme, I am Medication Safety, this year, Novant Health, a 15-hospital health system in North Carolina, focused on the importance of medication safety for the leaders of their safety program. Kristin Murphy, the leader of the Novant Health Medication Safety Program, shares her thoughts on medication safety.

The implementation of genetic testing for patients prescribed medications associated with progressive multifocal leukoencephalopathy is likely to improve safety outcomes.

Finerenone is a first in class nonsteroidal mineralocorticoid receptor antagonist indicated in adults with chronic kidney disease associated with type 2 diabetes mellitus.

Indya Wilson, MBA, CPhT, a pharmacy education support specialist at Novant Health Pharmacy Administration, discusses her role in the pharmacy and the benefits of alternative career paths for pharmacy technicians.

Furosemide exhibits diuretic action by inhibiting sodium and chloride reabsorption in the proximal and distal tubules and the loop of Henle.

Hannah Nivens, CPhT, a pharmacy distribution specialist at Novant Health Pharmacy Administration, discusses pharmacy distribution for pharmacy technicians.

As evidence for omega-3 continues to develop, pharmacists remain poised to guide patients toward the most indicated, safe, effective, and convenient options available.

Pharmacy technicians and pharmacy technician leadership from UPMC Presbyterian discuss the importance of diverse representation.

Cabotegravir showed promising results in preventing HIV transmission in men, women, and transgender women with similar rates of adverse events to oral PrEP options.

Pharmacy technicians and pharmacy technician leadership from UPMC Presbyterian discuss what being a Black health care workers means to them.

Pharmacy technicians and pharmacy technician leadership from UPMC Presbyterian discuss how they became pharmacy technicians in health-system pharmacies.

Each therapy presents a different but effective treatment option.

Because of CRS and neurologic toxicity risk, the therapy is available through a REMS program.

Both indications for the CTLA-4 inhibitor were approved by the FDA in 2022.

HER2-low disease demands a different approach from that of HER2-negative disease.

PARP inhibitors in particular have changed the therapeutic landscape for EOC.

Numerous clinical trials are investigating the next generation of PARPi.